Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT and Chemotherapy in Locally Advanced Pancreatic Cancer
NCT04603586Phase 2
Key facts
- Status
- Completed
- Start
- Nov 2020
- Primary completion
- Aug 2025
- Countries
- 1
- Sponsor
- Changhai Hospital
- Modality
- Small Molecules
- Conditions
- pancreatic adenocarcinoma (PDAC)
01
Overview
Phase 2, randomised, open-label trial of gemcitabine and paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Changhai Hospital. Started Nov 2020; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Patients with treatment-naive locally advanced pancreatic adenocarcinoma, ECOG 0-1, and adequate organ function.
04
Registry description
The aim of this study is to compare the safety and efficacy of SBRT in LAPC with different biological effective dose (BED) (\<70Gy Vs.\>70Gy ) , to identify a dose range that could achieve better survival benefit and minimize the toxicity of radiotherapy.
Beyond the preview
Go deeper on NCT04603586.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04603586.